TGFB1 and neoplasm: Conversely, inhibition of syndecan-2 not only attenuates TGF-β signaling, impedes PD-L1 expression, tumor growth, and metastasis, but also elevates immunotherapy susceptibility in breast tumors [182] (Table 1).